Abstract: The purpose of this study was to explore the association of genetic polymorphism of genes related to pharmacokinetics or pharmacodynamics with insulin resistance in children and adolescents with autism spectrum disorder (ASD) and treated with risperidone.
Autistic spectrum disorder (ASD) is a complex group of neurodevelopmental disorders displaying as impairment in social communication and social interaction and repetitive patterns of behaviour. Risperidone is a second-generation antipsychotic (SGA) drug, which was approved by the US Food and Drug Administration (FDA) for treating behavioural disturbance in children and adolescents with ASD [1] . In addition, there has recently been a large increase in the use of risperidone in children with a wide variety of psychiatric and non-psychiatric disorders [2] . Risperidone can offer some benefits over firstgeneration antipsychotic (FGA) drugs. For example, patients prescribed SGA drugs often show greater improvement in negative and cognitive symptoms, higher functional capacity, and have better quality of life with lower risks of extrapyramidal side effects (EPS) and tardive dyskinesia (TD) [3] . However, some concerns exist about treatment with risperidone as it may induce side effects such as hyperprolactinaemia [4] [5] [6] , hyperuricaemia [7] , weight gain [8] and dyslipidaemia [9] . Additionally, risperidone could increase the risk of type 2 diabetes [10] . There are published cases of new onset diabetes related to risperidone use [11] . In 2015, Burcu Ersoz Alan et al. [12] also found that the homeostasis model assessment of insulin resistance (HOMA-IR) significantly increased in young children after risperidone monotherapy.
The physiological pathways regulating the action of risperidone are complex and involve multiple molecules. In the liver, risperidone is extensively metabolized by cytochrome P450 2D6 (CYP2D6) to the active metabolite 9-hydroxyrisperidone [13] . Recently, more than 100 allelic variants and subvariants of the CYP2D6 gene have been reported. CYP2D6 polymorphisms are associated with the absence, decrease, increase or normal enzyme activity according to the Human Cytochrome P450 Allele Nomenclature Committee [14] . Genetic CYP2D6 status may correspond to a high degree of interindividual variability in clinical outcome and steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone [15] . A previous study reported the relationships of CYP2D6*10 (c.100 C>T) and metabolic parameters in children and adolescents treated with risperidone [16] . However, apart from plasma risperidone levels and their access to the brain, efficacy might depend upon the multidrug-resistant protein gene (MDR1 or ABCB1), which codes for P-glycoprotein (P-gp), the transmembrane efflux transporter. P-gp plays a major role in the absorption, distribution and elimination of drugs [17] . ABCB1 gene polymorphisms may play a role in patients who present with adverse effects. The strongest effect was between the ABCB1 2677 T/T and ABCB1 3435 T/T genotypes, which result in increased risperidone active moiety C/D level [18] . It might be that both of 3435T and 2677T ABCB1 variants may be associated with lower ABCB1 function and predispose to higher risperidone accessibility to the brain that would lead to metabolic adverse effects. In the brain, risperidone is a dopamine receptor D2 (DRD2) antagonist with strong affinity [19] . Impaired insulin secretion was found in DRD2 knockout mice [20] . Moreover, the A1 allele of the Taq1A polymorphism appears to be highly prevalent in individuals with type 2 diabetes [21] .
Several studies reported that glucose-insulin homeostasis is regulated by leptin (LEP) [22, 23] , ghrelin (GHRL) [24, 25] and brain-derived neurotrophic factor gene (BDNF) [26, 27] . LEP, which is a small peptide, regulates lipid levels, glucose homeostasis and insulin resistance [28] . Decreased levels of leptin were found in the patients treated with risperidone [29] . The frequency of the -2548 A allele of LEP gene in patients with type 2 diabetes was higher than normal [30] , and LEP G2548A was associated with metabolic syndrome (MetS) [31] . Overexpression of the ghrelin gene was shown to decrease insulin levels in mice, while its inactivation was shown to enhance insulin secretion and to prevent glucose intolerance [32] . In humans, the increased levels of ghrelin were found in patients treated with risperidone [29] The ghrelin variant, g.A-604G (rs27647), was associated with insulin levels at 2-hr post-oral glucose tolerance test (p = 0.009) in obese families [33] . Moreover, BDNF has been reported to influence the levels of fasting glucose and insulin sensitivity [34] . Risperidone administration is associated with decreased BDNF concentrations in rat brain [35] , and an association of the Val66Met polymorphism with SGA (clozapine)-induced increased fasting glucose levels was found [36] .
The exact mechanism for risperidone-related type 2 diabetes is ambiguous. Not all patients develop insulin resistance when treated with risperidone. This high interindividual variability in the risk of type 2 diabetes suggests that genetics may play an important role in a person's susceptibility to type 2 diabetes, making it a target for pharmacogenetic studies. There has been no study of the pharmacogenetics of risperidone-induced insulin resistance in ASD patients. The identification of genetic variants related to risperidone-induced insulin resistance may help in the selection of more suitable treatment for protecting against type 2 diabetes. Also, the patients with risperidone treatment necessitate long-term treatment. Identification of the risk of type 2 diabetes at initial diagnosis might limit critical adverse effects in several organ systems and improve patients' quality of life. The purpose of this study was to investigate the association between genetic polymorphisms of pharmacokinetics (CYP2D6, ABCB1) and pharmacodynamics (DRD2, LEP, GHRL and BDNF) genes and insulin resistance in ASD children and adolescents treated with risperidone.
Materials and Methods
Subjects. The outpatients who were followed up at Yuwaprasart Waithayopathum Child Psychiatric Hospital, Samut Prakan, Thailand, comprised 89 (81 males and 8 females) Thai children and adolescents aged 3-20 years. All patients (i) fulfilled the DSM-IV criteria, (ii) took daily doses of risperidone (iii), received a risperidone-based regimen for more than 4 weeks and (iv) had fasting status. Exclusion criteria for this study were as follows: (i) a known history of cardiovascular disease, diabetes, liver disease, kidney disease or other serious physical conditions, (ii) receiving concomitant treatments that could potentially affect glucose and insulin levels and (iii) inability to take medicine regularly or requirement for medication to be changed. The study was approved by the ethics committee of Ramathibodi Hospital (MURA2011/541). After the study was completely described, the parents of all children involved in the study gave informed written consent to participate.
Blood collection. All participants who passed inclusion and exclusion criteria were advised to take their medication and fast for approximately 12 hr before the morning blood draw. Blood was collected by venipuncture into EDTA whole blood and plain tubes between 8:00 and 10:00 a.m. for genotyping, and analysis of drug level and biochemical levels. The samples were kept at room temperature for 30 min. and then separated by centrifugation. Only plasma was stored 5 days at 2-8°C or 1 month at À20°C until measurement.
Genotyping analysis. We selected the candidate SNPs based on pathophysiologic pathways in literature reviews of risperidone-induced insulin resistance. Secondly, we examined the International HapMap Project database for minor allele frequency more than 0.05 in the Chinese Han in Beijing. Thirdly, significant association has been reported in previous studies; CYP2D6 [16, 37, 38] , ABCB1 [18] , DRD2 [21] , LEP [30, 31] , GHRL [33] , BDNF [36] . Candidate SNPs were identified from all three sources.
The pharmacokinetic and pharmacodynamic polymorphisms (CYP2D6, ABCB1, DRD2, BDNF, LEPTIN and GHRL) were genotyped using TaqMan-based analysis on an Applied Biosystems â ViiA TM 7 Real-Time PCR System (ABI, Foster City, CA, USA). Full details of the method have been described in our previous study [6] . Genotyping was detected by TaqMan single nucleotide polymorphism (SNP) genotyping assays, which were performed with primers of
GHRL -604G>A, rs27647), CYP2D6*4 (1846G>A, rs3892097), CYP2D6*10 (100C>T, rs1065852) and CYP2D6*41 (2988G>A, rs28371725). The CYP2D6 gene copy number variation was genotyped using TaqMan Copy Number Assays (Assay ID: Hs04083572_cn) in all samples. A copy number variation (CNV) result of 0 or 1, as compared with the normal 2, indicates CYP2D6 gene deletion, which is inferred as CYP2D6*5 according to the Human Cytochrome P450 Allele Nomenclature Committee (http:// www.cypalleles.ki.se/cyp2d6.htm). The CYP2D6-predicted phenotypes were determined following the activity score system [39] . Patients with activity score 0 were classified as poor metabolizers (PM). Patients with the activity score 0.5 were classified as intermediate metabolizers (IM), those with a value of 1.0-2.0 were classified as extensive metabolizers (EM), and those with a value >2 were classified as ultrarapid metabolizers (UM) [40] . The activity score system provided a more detailed classification for the subjects [41] .
Plasma risperidone measurement. Risperidone and 9-hydroxyrisperidone plasma concentrations were measured by a validated liquid chromatography-tandem mass spectrometry (LC-MS/ MS) method in accordance with the US Food and Drug Administration (US-FDA) guidelines [42] . The liquid chromatograph was an Agilent 1260 HPLC system, which was connected to an API 3200 (Framingham, MA, USA). Chromatographic separation was achieved on the C18 column (4.6 cm 9 50 mm; 1.8 mm particle size). Every 6 min., a sample was injected. Integration of peak areas and determination of the concentrations were performed with Analyst 1.5.2 software (Applied Biosystems). Quadratic regression with 1/ weighted concentrations was used. The mean inter-and intra-assay accuracy for both risperidone and 9-hydroxyrisperidone was set within AE15.0% relative error (RE) of nominal and precision 15.0% relative standard deviation (RSD).
Biochemical measurements. Plasma glucose was measured using FUJI DRI-CHEM 4000i system. The insulin levels were determined using a chemiluminescent immunoassay on the Immulite H2975 (Siemens Medical Solution Diagnostics, Massachusetts, USA). Insulin resistance was estimated using the HOMA-IR. The index of HOMA-IR was calculated according to the following formula: HOMA-IR = fasting insulin (lU/ml) 9 fasting glucose (mg/dl)/405. The HOMA-IR ≥ 2.6 was identified as insulin resistance in children and adolescents [43] .
Statistical analysis. Descriptive statistics were used to describe the clinical characteristics of the subjects. The Kolmogorov-Smirnov test was used to test for normal distribution at 95% confidence level. As the data are not normally distributed, they were expressed as a median and interquartile range (IQR). Genetic polymorphisms were assessed for concordance with Hardy-Weinberg equilibrium (HWE). Fisher's exact test or chi-squared test was used, as appropriate, to determine whether there is a significant association between the genetic polymorphisms and insulin resistance. Continuous variables were compared with nonparametric (Mann-Whitney U) tests between two groups. The combined effects of possible covariates (gender, age, drug levels, duration of treatment, comedication, body mass index and candidate genes) on metabolic adverse effects were investigated using multiple logistic regression analysis (forward stepwise method). All statistics were calculated using SPSS version 16 for Windows, and differences were considered to be significant when p values were <0.05.
Result
Patient characteristics. The demographic and clinical characteristics of the patients are summarized in table 1. Eighty-nine participants, the sample group, were mostly male (n = 81; 91.01%). All children and adolescents with ASD had a median age of 10.00 years (IQR: 8.90-13.40). The cohort was 48.31% children (3-9 years) and 51.69% adolescents (10-20 years). The median risperidone dose of the subjects was 1 mg/day (IQR: 0.50-1.50). The median duration of treatment was 63.92 months (IQR: 40.40-83.49). The median concentration of risperidone was 2.06 ng/ml (IQR: 0. 50-8.66) , and that of 9-hydroxyrisperidone was 9.37 ng/ml (IQR: 3.78-18.97), while active moiety concentration was 11.55 ng/ml (IQR: 5.48-26.88). The concentration ratio of risperidone/9-hydroxyrisperidone was 0. Association between insulin resistance and genetic polymorphism of genes related to pharmacokinetics. As for the CYP2D6-predicted phenotypes, patients were separated into three groups (UM, EM and IM). Most patients had the EM phenotype. There was no association between CYP2D6-predicted phenotypes and insulin resistance (table 3) . Concerning the CYP2D6 activity score, patients were separated into four groups (0.5, 1, 1.5 and 2). Most patients had CYP2D6 activity score 1. There was no association between CYP2D6 activity score and insulin resistance (table 3) . There was no association between ABCB1 polymorphisms and insulin resistance (table 3) . None of the risperidone-level parameters were associated with insulin resistance (table 4) .
Association between insulin resistance and genetic polymorphism of genes related to pharmacodynamics. This study investigated the association of insulin resistance and pharmacodynamic gene polymorphisms (DRD2 Tag- GA+AA genotype have significantly higher incidence of insulin resistance compared to GG genotype (odds ratio = 7.14, 95% confidence interval = 0.93-55.07, P=0.03) ( Table 5) . There was a possible trend toward significant association between LEP -2548 G>A and insulin resistance (odds ratio = 2.77, 95% confidence interval = 0.97-7.96, P=0.051). However, there was no association between polymorphisms of the DRD2 Tag-SNP (T>C), DRD2 Taq 1 A (C>T) and GHRL -604 A>G with insulin resistance.
Multivariate analysis of predictive factors for insulin resistance. The final multivariate model revealed that polymorphism of LEP (-2548 G>A) has a trend towards significance with insulin resistance (odds ratio = 3.51, 95% confidence interval = 0.97-12.72, p = 0.056). Polymorphism of BDNF (c.196G>A) was found to be statistically significantly associated with insulin resistance after adjustment for multivariate analysis (odds ratio = 13.74, 95% confidence interval = 1.39-135.73, p = 0.025) (table 6).
Discussion
Over the past decade, SGA drugs have been widely used in the treatment of schizophrenia in preference to FGA. Secondgeneration antipsychotics offer significant improvements over older FGA [3] . However, SGA could induce metabolic effects, including type 2 diabetes, with increased risk of eventual cardiovascular disease [10, 44, 45] . A retrospective study suggests that the prevalence of glucose intolerance and type 2 diabetes is higher in patients treated with SGA drugs than in those treated with FGA [46] . Moreover, the risk of type 2 diabetes related to treatment with antipsychotic drugs seems to be greatest in younger patients (≤24 years) [47] . The exact mechanism for risperidone-related type 2 diabetes remains unclear. Identification of the genetic variants that influence drug-related type 2 diabetes might aid selection of more suitable drugs and may assist in elucidating the mechanisms underlying the adverse effects. To our knowledge, this is the first study to investigate the association between genetic polymorphisms and insulin resistance in ASD children and adolescents treated with risperidone. Concerning the effect of pharmacokinetics gene polymorphisms and risperidone plasma concentration on insulin resistance, CYP2D6 is the main subunit associated with conversion of risperidone to the active metabolite 9-hydroxyrisperidone. CYP2D6*1, *2, *5, *10, *41 are the five most common alleles in Thai children with ASD [37] . Both *1 and *2 have normal function. CYP2D6*4 is non-functional; therefore, CYP2D6*4 was also selected. Previous studies of ASD children and adolescents by our research team found that polymorphic variants of CYP2D6 have been shown to influence risperidone metabolism, and the metabolic ratio (risperidone/9-hydroxyrisperidone) [38, 48] . Considering the association between CYP2D6 gene polymorphisms and metabolic adverse effects, the study by Santos-J unior et al. [16] determined the relationship between CYP2D6*10 (c.100 C>T) and metabolic parameters in children and adolescents treated with risperidone. They reported that homozygosity (C/C and T/T) was associated with a higher HOMA-IR. The CYP2D6 poor metabolizer phenotype appears to be associated with risperidone-induced ADRs and discontinuation due to ADRs [49] .
Our study patients were grouped according to the CYP2D6-predicted phenotypes. We found that there was no association between predicted phenotypes and insulin resistance. Moreover, concerning the CYP2D6 activity score, there was also no association between CYP2D6 activity score and insulin resistance. This result is consistent with our previous study in which we found that there was no association between CYP2D6 polymorphism and metabolic effect (weight gain) in ASD children and adolescents treated with risperidone [50] . This negative finding may be explained in several ways. Firstly, the CYP2D6 poor metabolizer phenotype is not found in Thai populations, and generally low in East Asians (average 0.4), whereas the incidence of poor metabolizer phenotypes is highest in Europeans (average, 5.4%) and the Ashkenazi Jewish population (6%) [51] . Secondly, it is also possible that even if CYP2D6 polymorphisms influence risperidone plasma concentration, the variation of CYP2D6 still may have little clinical relevance. Thirdly, the CYP2D6 gene may not be directly associated with metabolic adverse effects. It is possible that other gene polymorphisms such as LEP and BDNF could be involved. Therefore, the involvement of CYP2D6 polymorphism on metabolic adverse effects including insulin resistance requires further evaluation.
The ABCB1 gene is an efflux pump that removes a variety of lipophilic drugs from the intracellular space. ABCB1, expressed at the blood-brain barrier, regulates the entry of antipsychotic drugs from the blood system into the central nervous system. ABCB1 is also expressed at the luminal membrane of the endothelial cells and the small capillaries. However, the current study found that there was no association between ABCB1 polymorphisms (G2677T and C3435T) and steady-state plasma concentration of risperidone and its metabolite (data not shown). Our data are consistent with Yasui-Furukori et al. [52] , who reported that the ABCB1 variants were not associated with steady-state plasma concentration of risperidone or 9-hydroxyrisperidone. There was no association between ABCB1 polymorphisms (G2677T and C3435T) and insulin resistance in this study. This is the first study of the association between ABCB1 polymorphism and insulin resistance. Further studies are needed to assess the role of the ABCB1 variants in risperidone level and insulin resistance.
Regarding risperidone plasma levels, our study found that there was no association between risperidone levels and insulin resistance. Our finding is consistent with the result of Youngster et al. [53] , who reported no association between risperidone levels and metabolic effects (weight gain) in autism treated with risperidone [53] . Moreover, in adult psychiatric patients, risperidone plasma levels have long been known to be poorly correlated with clinical outcome [54] . There are several reasons that risperidone plasma concentrations and metabolic adverse effects, including insulin resistance, appear unrelated. Firstly, the drug levels in ASD children and adolescents might not reach the minimum toxic concentration. Secondly, the effect of the drug should concern both pharmacokinetics and pharmacodynamics. Thirdly, metabolic effects might derive from genetic polymorphisms. Therefore, therapeutic drug monitoring may be reserved for special patient populations or in cases of suspected problems with adherence. Concerning the pharmacodynamic gene polymorphisms, BDNF has been reported to impact glucose-insulin homeostasis [27] , and decreased serum BDNF levels were found in the patients with type 2 diabetes mellitus [26, 55] . The study by Nakagawa et al. [55] revealed that BDNF enhances insulin activity in diabetic mice. Moreover, BDNF directly affects the pancreas and normalizes the function of islets [56] . Angelucci and colleagues demonstrated that BDNF levels in rat brains decreased after treated with risperidone [35] . Reduced brain BDNF after risperidone medication may be a part of the mechanism causing risperidone-induced type 2 diabetes. Moreover, the polymorphisms of BDNF (c.196G>A) change the intracellular trafficking and activity-dependent secretion of BDNF [57] .
Recently, BDNF Val66Met polymorphism was established as a risk factor for insulin in patients treated with SGA [58] . Our study found that BDNF A allele was significantly associated with insulin resistance (after adjustment for multivariate analysis) among ASD children and adolescents treated with risperidone. Consistent with this finding, Bonaccorso et al. found that BDNF c.196G>A (Val66Met) polymorphism in patients with bipolar disorder showed a greater increase in TG/HDL ratio, which is a surrogate marker for insulin resistance [59] , after 3 months of treatment with risperidone [60] . Moreover, Burghardt et al. [58] reported that the BDNF Met allele in combination with SGA medications is associated with higher HOMA-IR values. Insulin resistance and hyperglycaemia could further increase the risk of MetS-associated cardiovascular disease (CVD) [61, 62] . Taken together, this may indicate that the patients treated with risperidone with BDNF c.196G>A (Val66Met) polymorphism may have greater susceptibility to type 2 diabetes and MetS along with CVD.
Regarding LEP gene polymorphism, leptin hormone regulates glucose homeostasis and insulin resistance [28] . Leptindeficient rodents and humans with a loss of adipose tissue are hypoleptinaemic and have hyperinsulinaemia, insulin resistance and hyperglycaemia [63] [64] [65] . Thus, inappropriately low leptin levels result in perturbed glucose homeostasis. Indeed, risperidone reduced both insulin-mediated protein kinase B activation and leptin-induced signal transducer and activator of transcription 3 (STAT3) phosphorylation, which led to insulin and leptin resistance [66] . Moreover, the LEP-2548 G-allele was associated with lower mRNA expression and lower leptin plasma levels [67] . Our study found that the 2548 G-allele is related to insulin resistance. This is the first study of the association between LEP polymorphism and insulin resistance in ASD patients treated with risperidone. The 2548 G-allele did not remain statistically significantly associated with insulin resistance after adjustment for multivariate analyses. Therefore, the involvement of LEP polymorphism on risk of type 2 diabetes requires further evaluation. There were some limitations in this study. Firstly, the size of our sample was relatively small; these results need to be validated with a larger independent sample of patients. Secondly, other genetic polymorphisms, which might affect insulin resistance, including 5-hydroxytryptamine (serotonin) [68] , were not investigated. Thirdly, current guidelines state that HOMA index does not provide clear insulin resistance correlation in children and adolescents, even obese ones, because of differences in gender, age, physical activity and others [69] . There is no clear widely accepted cut-off. However, HOMA-IR, which is the most widely used of the surrogate measures in children, is highly correlated with fasting insulin in children and adults [70] . Fourthly, no data were collected to describe baseline metabolic parameters before risperidone treatment. Thus, it was not possible to analyse data for changes in those parameters over time related to the use of risperidone. A further longitudinal prospective study is needed.
Conclusions
In conclusion, to the best of our knowledge, this is the first study to determine the association of genetic polymorphisms and insulin resistance in ASD paediatric patients treated with risperidone. Our result indicates that there is no effect of pharmacokinetic gene polymorphisms (CYP2D6 and ABCB1) and risperidone plasma concentration on insulin resistance. Insulin resistance was related to LEP 2548 G>A and BDNF 196 G>A polymorphism. This finding might be useful to provide opportunities for personalized medicine in the predictive assessment of the risk of type 2 diabetes and to minimize the risk of metabolic syndrome as well as optimizing the treatment of ASD children and adolescent. Also, patients receiving risperidone usually require long-term therapy. Initial diagnosis of type 2 diabetes and management of treatment are necessary to reduce the morbidity associated with type 2 diabetes in ASD children and adolescents.
